Abstract
Muscle fibrosis represents the end stage consequence of different diseases, among which muscular dystrophies, leading to severe impairment of muscle functions. Muscle fibrosis involves the production of several growth factors, cytokines and proteolytic enzymes and is strictly associated to inflammatory processes. Moreover, fibrosis causes profound changes in tissue properties, including increased stiffness and density, lower pH and oxygenation. Up to now, there is no therapeutic approach able to counteract the fibrotic process and treatments directed against muscle pathologies are severely impaired by the harsh conditions of the fibrotic environment. The design of new therapeutics thus need innovative tools mimicking the obstacles posed by the fibrotic environment to their delivery. This review will critically discuss the role of in vivo and 3D in vitro models in this context and the characteristics that an ideal model should possess to help the translation from bench to bedside of new candidate anti-fibrotic agents.
| Original language | English |
|---|---|
| Pages (from-to) | 64-77 |
| Number of pages | 14 |
| Journal | Advanced Drug Delivery Reviews |
| Volume | 129 |
| DOIs | |
| Publication status | Published - Apr 1 2018 |
Fingerprint
Keywords
- 3D in vitro models
- Muscular dystrophy
- Skeletal muscle fibrosis
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
Tackling muscle fibrosis : From molecular mechanisms to next generation engineered models to predict drug delivery. / Bersini, S.; Gilardi, M.; Mora, M.; Krol, S.; Arrigoni, C.; Candrian, C.; Zanotti, S.; Moretti, M.
In: Advanced Drug Delivery Reviews, Vol. 129, 01.04.2018, p. 64-77.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Tackling muscle fibrosis
T2 - From molecular mechanisms to next generation engineered models to predict drug delivery
AU - Bersini, S.
AU - Gilardi, M.
AU - Mora, M.
AU - Krol, S.
AU - Arrigoni, C.
AU - Candrian, C.
AU - Zanotti, S.
AU - Moretti, M.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Muscle fibrosis represents the end stage consequence of different diseases, among which muscular dystrophies, leading to severe impairment of muscle functions. Muscle fibrosis involves the production of several growth factors, cytokines and proteolytic enzymes and is strictly associated to inflammatory processes. Moreover, fibrosis causes profound changes in tissue properties, including increased stiffness and density, lower pH and oxygenation. Up to now, there is no therapeutic approach able to counteract the fibrotic process and treatments directed against muscle pathologies are severely impaired by the harsh conditions of the fibrotic environment. The design of new therapeutics thus need innovative tools mimicking the obstacles posed by the fibrotic environment to their delivery. This review will critically discuss the role of in vivo and 3D in vitro models in this context and the characteristics that an ideal model should possess to help the translation from bench to bedside of new candidate anti-fibrotic agents.
AB - Muscle fibrosis represents the end stage consequence of different diseases, among which muscular dystrophies, leading to severe impairment of muscle functions. Muscle fibrosis involves the production of several growth factors, cytokines and proteolytic enzymes and is strictly associated to inflammatory processes. Moreover, fibrosis causes profound changes in tissue properties, including increased stiffness and density, lower pH and oxygenation. Up to now, there is no therapeutic approach able to counteract the fibrotic process and treatments directed against muscle pathologies are severely impaired by the harsh conditions of the fibrotic environment. The design of new therapeutics thus need innovative tools mimicking the obstacles posed by the fibrotic environment to their delivery. This review will critically discuss the role of in vivo and 3D in vitro models in this context and the characteristics that an ideal model should possess to help the translation from bench to bedside of new candidate anti-fibrotic agents.
KW - 3D in vitro models
KW - Muscular dystrophy
KW - Skeletal muscle fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85043601302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043601302&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2018.02.009
DO - 10.1016/j.addr.2018.02.009
M3 - Review article
AN - SCOPUS:85043601302
VL - 129
SP - 64
EP - 77
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
SN - 0169-409X
ER -